



EFFICACY OF ESWT AND NUTRACEUTICAL SUPPLEMENTATION VS ESWT-ONLY IN THE TREATMENT OF CHRONIC LATERAL EPICONDYLITIS: A RANDOMIZED CONTROLLED TRIAL

Utpalendu
Debnath*

MBBS, MD(PMR), Department of Physical Medicine and Rehabilitation, IGM Hospital, Agartala-799009. *Corresponding Author

ABSTRACT

Introduction: Tendinopathy is common in professional athletes as well as in sedentary people. It occurs 30% -50% of all sports related injuries. Injection of autologous blood has been reported beneficial for the treatment of tendinopathy. It is hypothesized that transforming growth factor- and basic fibroblast growth factor carried in the blood will act as humoral mediators to induce the healing cascade. Musculoskeletal ultrasound can document the pathology prior to the injection and accurately identify the site for injection. It also helps in monitoring tendon healing. **Materials And Methods:** This randomized controlled trial was carried out after obtaining permission from Research Ethics Board between September 2023 to August 2024 in the Department of Physical Medicine and Rehabilitation (PMR), IGM Hospital, Agartala. A total of 30 patients with lateral epicondylitis were included in this study using block of four randomization technique. The independent variable considered were age, sex, occupation, duration and side of affection. The intervention group received ESWT and nutraceutical supplementation whereas the control group received ESWT only. **Results And Observations:** Out of 30 patients recruited, 18 patients were female (60%) and 12 were males (40%). The intervention group consisted of 8 females and 7 males with a mean age group of 47.20 ± 10.06 years while the control group consisted of 10 females and 5 males with a mean age group of 46.20 ± 8.79 years. There was significant improvement in VAS and PRTEE score in ESWT and nutraceutical supplementation group compared to control group in 6 months follow up. There were also significant improvement in neovascular, echotexture grading and tendon size in ESWT and nutraceutical supplementation group compared to the control group in 6 months follow-up. **Conclusion:** The study showed that ESWT and nutraceutical supplementation is significantly more effective in reducing pain and disability in resistant lateral epicondylitis at 6 months as compared to ESWT only. This study also confirmed that there was significant improvement of ultrasound parameters in ESWT and nutraceutical supplementation group compared to ESWT only group and may be considered as an alternative to surgery in resistant lateral epicondylitis.

KEYWORDS : Tendinopathy, Lateral epicondylitis, Extracorporeal shock wave therapy (ESWT) Patient Rated Tennis Elbow Evaluation (PRTEE), Musculoskeletal ultrasonography.

INTRODUCTION

Tendon pain is common in professional athletes as well as in sedentary people. It occurs 30% -50% of all sports related injuries.¹ Tendinopathy (often called tendonitis or tendinosis) is the most common tendon disorder. It is characterized by activity related pain, focal tenderness and decreased range of movement in the affected area. Tendinopathy can occur in any tendon. Tendinopathy is not characterized by an inflammatory response but rather infiltration of fibroblasts and vessels ensuing chronic cycle of tendon degeneration and repair resulting in a weakened tendon.² Lateral epicondylitis also known as the tennis elbow is a term used to describe myriad of symptoms around the lateral aspect of the elbow which occurs more frequently in nonathletes than athletes.³ The disorder arises as a result of repetitive movements of the involved muscles particularly in the working age group. The disease imparts significant disability in terms of the quantity and quality of work done. Tennis elbow may also cause significant weakness of grip strength particularly with the elbow in extension.⁴ Incidence of injury has been reported in various forms. For instance, in club gymnastics injury rates vary between 2 to 4 and 39.9 per 100 school children per year.⁵ The peak incidence is in the early fifth decade and a nearly equal gender incidence is seen.⁶ The pathology of lateral epicondylitis results from overuse of the extensor muscles leading to degenerative pathology of the involved tendons.⁷ Although it is known as a tendonitis, histopathologic studies have shown that it is associated with few inflammatory cells but more associated with hypertrophy of fibroblasts, abundant disorganized collagen, hyperplasia of vascular elements, apoptosis and extracellular matrix breakdown.⁸

The diagnosis of tennis elbow is usually made clinically by localizing discomfort at the origin of the extensor carpi radialis brevis. Tenderness is present over the lateral epicondyle approximately 5 mm distal and anterior to the midpoint of the lateral epicondyle. Pain usually is exacerbated by dorsiflexion of wrist against resistance and

forearm supination and on grasping objects.³ Resistant lateral epicondylitis will be diagnosed if there is persistent pain and tenderness on or near lateral epicondyle despite all conservative treatments spanning for a minimum period of 6 months along with 2 of 3 pain provocative tests- gripping, Cozen's test and Mill's manoeuvre.⁹ Numerous different methods have been proposed to treat tendinopathy, such as eccentric training, the injection of corticosteroids and sclerosants, prolotherapy, extracorporeal shockwave therapy and glyceryltrinitrate patches¹⁰. Corticosteroid injection has been shown to provide short term relief but relapse rates are high. Recent literature suggests that corticosteroid injections may actually have deleterious effects after their short-term pain relief.¹¹ Currently, eccentric training is the first choice of treatment of most practitioners, although the methodological quality of the studies suggesting efficacy has recently been questioned.^{12,13}

It has been demonstrated that ESWT is effective for tendinopathy, leading to a success rate ranging from 55–90%. In particular, recovery is achieved in 83% of calcific tendonitis of the shoulder, 55% of sub-acromial impingements, 76% of epicondylitis, 74% of plantar fasciitis, 90% of peritrochanteric bursitis, 82% of Achilles tendinopathy, and 86% of patellar tendinopathy.¹⁴

ESWT stimulates soft-tissue healing through inhibition of afferent pain-receptor function, down regulation of expression of inflammatory cytokines, improvement of cellular proliferation, synthesis of extracellular matrix, and enhanced angiogenesis.

Recently several clinical studies have demonstrated that exogenous supplementation with micronutrients can facilitate recovery of tendinopathies.^{15–17} The main substances essential for tendon healing include arginine, polyphenols (Vinitrox™ Bio Serac Laboratories SAS, Bram, France), collagen, methylsulfonyl-methane (MSM), vitamin C, and bromelain.¹⁸

The goal of this study was to assess the effects of our synergistic therapy using clinical and functional recovery indexes to assess patients affected by lateral elbow tendinopathy.

AIMS AND OBJECTS

1. To study the efficacy of ESWT and nutraceutical supplementation vs ESWT-only in the treatment of lateral epicondylitis
2. To assess the tendon healing by musculoskeletal ultrasonography after the procedure.

MATERIAL AND METHODS

This randomized controlled trial was carried out after obtaining permission from Research Ethics Board between September 2023 to August 2024 in the Department of Physical Medicine and Rehabilitation (PMR), IGM Hospital, Agartala. A total of 30 patients with lateral epicondylitis were included in this study using block of four randomization technique.

Inclusion Criteria:

- Tendinopathy more than 6 months
- Ultrasound features of tendinopathy
- Pain severity with minimum score of ≥ 5 based on 10 scale VAS (Visual Analogue Scale)
- Willingness to comply with the treatment and follow-up assessments

Exclusion Criteria:

- Prior tendon rupture or surgery
- History of steroid injection in last 6 weeks
- History of any malignancy
- Systemic illnesses including ischemic heart disease, diabetes, rheumatoid arthritis, hepatitis
- Any fracture, bony malformation, articular lesions at elbow
- Patients who showed contra-indications to ESWT (Pacemaker, pregnancy, systemic or in-situ neoplasia, local infection, history of epilepsy, severe coagulopathies)

Procedure

Patient's baseline complete haemogram and musculoskeletal ultrasonography of the affected elbow was taken before the intervention.

1. For each condition, the patients were sub-divided into a control group, treated with ESWT, and an experimental group, treated with a combination of ESWT and the dietary supplement (DS). Dietary Supplement (DS) containing methylsulfonylmethane (MSM), hydrolyzed swine collagen (Type I and Type II), L-arginine and L-lysine, vitamin C, Chondroitin Sulfate, Glucosamine, Curcuma longa extracted to obtain curcuminoids, dry *Boswellia serrata* extracted to obtain acetyl-11-keto-b-boswellic acid (AKBA). The dietary supplement was consumed twice a day for 1 month, then once a day for an additional month. We advised patients to take the dietary supplement at roughly the same time every day on an empty stomach in order to increase its bioavailability. VAS was selected to measure the perceived pain intensity, by asking the patient to report a value between 0–10 cm along a horizontal line (10 $\frac{1}{4}$ severe pain; 0 $\frac{1}{4}$ no pain). A two-centimetre change was considered clinically relevant⁶. The PRTEE, formerly known as the Patient-Rated Forearm Evaluation Questionnaire (PRFEQ), is a 15-item questionnaire designed to measure forearm pain and disability in patients with lateral epicondylitis. It consists of two subscales (pain and function). The sensitivity and specificity values associated with the PRTEE were 0.94 (95% CI=0.83–0.98) and 0.78 (95% CI=0.58–0.91) respectively.¹⁹ All 30 patients were subjected to one cycle of three high-energy Extracorporeal Shock Wave Therapy sessions, performed once a week for three consecutive weeks, with 1,700–2,000

shocks applied with a flux energy density of 0.12–0.35- mJ/mm² using a Storz Medical Duolith SD1a machine.

Insert Figure No 1 And 2 Here

Outcome variables were measured at baseline (i.e. before intervention) and follow up assessment were done at 2 weeks, 3 months and 6 months after the injection. But ultrasonography examination was carried out at baseline, 3 months and 6 months follow-up.

The outcome measures considered in this study were

1. Visual Analogue Scale (VAS)
2. Patient Rated Tennis Elbow Evaluation (PRTEE)
3. Ultrasonographic assessments

2. Visual Analogue Scale (VAS)²⁰ for pain is a 100 cm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable". The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in centimeters from the left hand end of the line to the point that the patient marks.

3. Patient Rated Tennis Elbow Evaluation (PRTEE)²¹:- The PRTEE, formerly known as the Patient-Rated Forearm Evaluation Questionnaire (PRFEQ), is a 15-item questionnaire designed to measure forearm pain and disability in patients with lateral epicondylitis. It consists of two subscales (pain and function). The sensitivity and specificity values associated with the PRTEE were 0.94 (95% CI=0.83–0.98) and 0.78 (95% CI=0.58–0.91) respectively.²¹

4. Sonographic assessment²²

I. Echotexture grading scale

0 Normal

1a Hypoechoogenicity less than one third of the tendon

1b Hypoechoogenicity in between one third to two third of the tendon

1c Hypoechoogenicity in more than two third of the tendon

2 Partial thickness tear

3 Full thickness tear

II. Neovascularization grading scale-

0 No neovascularization

1 Neovessels on the tendon surface

2 1 or 2 intratendinous neovessels

3 3 or more intratendinous neovessels

III. Tendon size- In milimeter.

IV. Calcification-

Insert image no 3, 4, and 5 here

Statistical analysis:

Data were collected in a pre-tested proforma. Analysis was done using Statistical Package for the Social Sciences, SPSS 21 version. For descriptive statistics, mean and standard deviation was used. For continuous variable Student's t-test was used. Chi-square and Fisher's exact test were used for categorical variables. P-value < 0.05 was taken as statistically significant.

RESULTS

Table 1 shows the baseline characteristics of the study participants. 18 patients were females which constituted 60% of total patients and 12 were males constituting 40% of total sample size. The ESWT and nutraceutical supplementation group consisted of 8 females and 7 males with a mean age group of 47.20 ± 10.06 years while the control group (ESWT only group) consisted of 10 females and 5 males with a mean age group of 46.20 ± 8.79 years. The baseline characteristics of

both the groups were shown in Table 1 and showed no statistically significant difference in both the groups. As far the side of involvement is concerned, majority of patients in both the groups had right sided involvement. The mean duration of symptoms in ESWT and nutraceutical supplementation group was 8.47 ± 2.31 months and where as in the ESWT-only group it was 7.81 ± 2.93 months.

Inset Table No 1 Here

Table 2 shows the mean improvement of VAS score which was found to be statistically significant ($p < 0.05$) in the ESWT plus nutraceutical and ESWT only groups. At 2 weeks and 3 months follow-up, ESWT only group showed more improvement compared to the group receiving ESWT plus nutraceutical. But at 6 months follow-up, ESWT plus nutraceutical group showed more improvement of VAS score compared to the ESWT-only group and which was statistically significant ($p < 0.001$).

Inset table no 2 here

Table 3 shows the mean improvement of PRTEE score which was found to be statistically significant in both the groups at 2 weeks and 6 months follow-up. But ESWT plus nutraceutical group showed more improvement of PRTEE score compared to the ESWT-only group at 6 months follow-up ($p < 0.001$).

Inset table no 3 here

Table 4 shows echotexture improvement in both the group having normal echotexture pattern that is grade 0 at the end of three months follow-up however the group receiving ESWT-only group showed more improvement compared to the group receiving ABI in terms of echotexture grading improvement ($p < 0.001$). But at the end of 6 month improvement in term of normal echotexture grading pattern was more significant in the group receiving ESWT plus nutraceutical as compared to the group receiving ESWT-only ($p = 0.000$).

Inset table no 4 here

Table 5 shows that there were improvement in terms of neovascularization in both the groups at 3 month and 6 month follow-up but at the end of 6 month ESWT plus nutraceutical group showed more improvement compared with the group receiving ESWT-only with no statistical significance ($p > 0.05$).

Inset table no 5 here

Table 6 shows that the mean reduction in tendon size were found to be statistically significant ($p < 0.05$) in both the ESWT plus nutraceutical and ESWT-only group. But ESWT plus nutraceutical group showed more improvement at 6 month compared to the ESWT-only group.

Inset Table No 6 Here

DISCUSSION

Tennis elbow is a common tendinopathy that can be quite resistant to treatment and often affect the daily activities of the people. Many conservative treatment strategies have been used in treatment of lateral epicondylitis as first line but the treatment response is often inadequate. Conservative management like activity restrictions, orthotics and splints, NSAIDs, physical modalities has been tried. A recent Cochrane review²³ concluded that steroid injection has only short term effect and has poor outcome in long term. Surgical treatment remains a last option and many a times it involves considerable cost, morbidity and complications. Most of the people refuse to opt for surgical treatment because of fear and ignorance. Thus there is a question for effective alternative conservative therapies. Growth factors have shown promising results in field of tendon injury and repair. These are usually given in form of whole blood, platelet rich plasma or bone marrow aspirate injection. According to recent report by Jindal et al, autologous blood injection showed marked improvement in patients with chronic refractory lateral epicondylitis.²⁴

ESWT, initially introduced for the treatment of nephrolithiasis, has become a viable option for the treatment of different soft-tissue disorders⁸ such as calcific tendinopathy of the rotator cuff, lateral elbow tendinopathy, and insertional Achilles tendinopathy. ESWT modifies cell membrane and cytoplasmic organelles, resulting in nucleus stimulation. All of these changes lead to synthesis of proteins, nitric oxide (NO), and specific growth factors (GF) which activate several biological processes.²⁵ Erroi et al. demonstrated that both ESWT and platelet-rich plasma (PRP) injections are effective in the treatment of insertional Achilles tendinopathy in people who participate in sports. PRP is a concentrate of platelet-rich plasma protein derived from the patient's own blood containing growth factors, with healing, regeneration, and anti-inflammatory effects^{21–23}. Lee et al. have reported optimal outcomes after ESWT in the treatment of chronic refractory Achilles tendinopathy. Frassanito et al.²⁶ stated that a treatment of kinesio taping, followed by ESWT, can be an effective treatment in patients affected by calcific shoulder tendinopathy. Kinesiotaping indeed can be considered an adjuvant therapy, which improves the regenerative effects of ESWT. Li et al. have demonstrated the effectiveness of ESWT in shoulder pain relief in patients affected by chronic rotator cuff tendinopathy. Moreover, Vulpiani et al.²⁷ showed that ESWT had better clinical outcomes at 6 and 12 months follow-up when compared to Cryo-US in the treatment of symptomatic chronic lateral epicondylitis.

A more recent retrospective study, conducted by Chouet al.²⁸ underlined the effectiveness of performing ESWT in the management of chronic rotator cuff tendinitis or partial tears of the rotator cuff before undergoing surgery. They compared two groups of patients, an athletic group and a non-athletic group, and observed a faster recovery with a rate of satisfaction greater than 50% in both groups.

Gumina et al.²⁹ demonstrated that an oral supplement containing methylsulfonylmethane, arginine L-alpha-ketoglutarate, hydrolyzed type I collagen bromelain, and grape juice (Tenosan), could reduce shoulder pain and improve healing of large rotator cuff tears after arthroscopic repair. Merolla et al.³⁰ used a dietary supplement containing *Boswellia serrata* and *Curcuma longa* (Tendisulfur, Laborest SpA, Nerviano, Italy), which showed short-term effectiveness in post-operatively reducing pain after rotator cuff tear repair surgery. Notarnicola et al.⁵ evaluated the efficacy of combined treatment with ESWT and arginine supplementation in patients with Achilles tendinopathy, observing an improvement of the therapeutic response. Another interesting study was conducted by Baliet al.³¹ who evaluated the effects of an oral supplement composed by mucopolysaccharides, type I collagen, and vitamin C in the treatment of Achilles tendinopathy. Their results show that the combination of the aforementioned supplement and either eccentric training or passive stretching provides further benefits compared to physical therapy alone. Considering the wide consensus of ESWT in the literature, we believe that ESWT represents the best physical therapy to provide an effective recovery for tendinopathies, and Tendisulfur Forte may be useful in reducing inflammation and the possibility of recurrence because of its key features. Indeed, shock wave therapy increases bioavailability of the supplement to the tendon tissue⁶, due to the neo-angiogenic properties of ESWT^{32,33}. To confirm the positive effect of the association of Tendisulfur Forte and ESWT, our study showed that patients in the Tendisulfur Forte group reduced their use of NSAIDs during the 2 months of treatment when compared to the control group. Moreover, we observed a greater decrease of pain in the Tendisulfur Forte group and an improvement of tendon healing after 30 days of treatment. We report no side-effects in all patients treated with nutraceutical supplement.

The present study reveals that mean age of the study

population group were 47.20 ± 10.06 years in ABI group and 46.20 ± 8.79 years in steroid group. In a study conducted by Jindal et al²⁴, the mean age of study group were 37.32 ± 7.52 years in ABI group and 39.04 ± 6.67 years in steroid group. Lateral epicondylitis is most commonly seen in working population because this condition is basically an overuse syndrome.

In present study, housewives constituted 50% and manual labourers constituted 16.66% of total patients. In a study conducted by Gani N et al¹⁴, 71 % of total females were housewives and 77% of total males were manual labourers. This could be explained by the repeated microtrauma to extensor carpi radialis brevis due to overuse of this muscle in activities involving repetitive manual works.

The mean duration of symptoms in ESWT and nutraceutical supplementation group was 8.38 ± 2.35 months where as in ESWT only group it was 7.72 ± 2.11 months. Bostan B et al³⁴ also found in their study that mean duration of the symptoms was 8.4 months. The subjects selected for this study were resistant cases who had already been tried with conservative management and have not improved symptoms for at least six months.

The ESWT and nutraceutical supplementation group consisted of 8 females and 7 males whereas steroid group consisted of 10 females and 5 males. It was found that females were more commonly affected than males as in previous studies. This higher incidence in females may be explained by the type of household activities where repeated supination and pronation is required.

Majority of patients in both the groups had right sided involvement which was their dominant side. In the study conducted by Jindal et al²⁴, who also compared autologous blood injection and steroid injection in patient suffering from chronic lateral epicondylitis, they found similar findings about the laterality of this condition. Majority of their patients had right sided dominant hand involvement. These findings explain the theory of overuse injury as the pathogenesis of lateral epicondylitis.

In the present study, there was significant improvement in the mean of VAS score in both the groups at 2 weeks, 3 months and 6 months follow up ($p < 0.05$).

In ESWT and nutraceutical supplementation group, the mean VAS score improved from 6.24 ± 0.72 to 4.45 ± 1.04 at 2 weeks and further improved to 3.18 ± 1.18 and 1.49 ± 0.51 at 3 months and 6 months follow up respectively ($p < 0.05$).

Arik HO et al²⁸ also found that there was significant improvement of VAS score in both the ABI and steroid groups at 15, 30, 90 and 180 days follow-up but ABI group showed more significant improvement of VAS score at 90 and 180 days follow-up compared to the steroid group. The finding was also in concordance with the present study.

There was improvement of PRTEE scores in both ESWT and nutraceutical supplementation and ESWT only groups at 2 weeks and 6 months follow-up. The control group showed more significant improvement in PRTEE score compared to ESWT and nutraceutical supplementation group ($p < 0.05$) at the end of 2 weeks follow up, even though both the groups had significant reduction in the score. However ESWT and nutraceutical supplementation group showed more significant improvement in PRTEE score when compared to the steroid group at the end of 6 month follow-up ($p < 0.01$).

There was significant improvement of echo-texture grading in ESWT and nutraceutical supplementation group compared to ESWT only group in 3 months and 6 months followup. In a

study conducted by Suresh SPS et al²⁹, they found that hypo-echoic change score decreased from 6.45 points (at baseline) to 3.85 points at 10 months follow-up and this decrease was found to be statistically significant ($p = 0.001$). Neo-vascularity score decreased from pre-procedure mean score of 6.10 points to post procedure mean of 3.60 points, at 10 months where the mean decrease score was found to be statistically significant ($p = 0.001$). In the present study we could not find any significant improvement in terms of neo-vascularity scores. This probably would be because of our short term follow up till only 6 months and probably long term follow up could have shown changes in terms of neovascularitiescore.

There was significant reduction of tendon size in both the groups but size reduction was more in ESWT and nutraceutical supplementation group when compared to the group receiving ESWT only at 6 months follow-up. In ESWT and nutraceutical supplementation group baseline mean tendon size was 4.65 ± 1.02 mm which reduced to 3.78 ± 0.75 mm and 3.27 ± 0.62 mm at 3 months and 6 months follow-up respectively. On the other hand ESWT only group baseline tendon size was 4.61 ± 0.26 mm which reduced to 3.44 ± 0.50 mm and 3.65 ± 0.51 mm at 3 months and 6 months follow-up respectively. In a study conducted by Gautam VK et al³⁰, they also found similar reduction in tendon size in ESWT and nutraceutical supplementation group when compared to that of ESWT only group.

Patients who received the ESWT and nutraceutical supplementation and ESWT only did not have any serious adverse effects during or after procedure.

Additionally, there is no consensus about frequency, number of ESWT and nutraceutical supplementation in chronic resistant lateral epicondylitis. However the present study showed significant pain and function improvement. Hence the results of this study may provide insights into effect of ESWT and nutraceutical supplementation in chronic tendinopathies. It may also contribute to identify as one approach for ESWT and nutraceutical supplementation in resistant tennis elbow.

Long term follow up may require for studying the long term effect of ESWT and nutraceutical supplementation.

CONCLUSION

The present study was done to find out the efficacy of ESWT and nutraceutical supplementation in chronic lateral epicondylitis to improve pain and function. The study showed that ESWT and nutraceutical supplementation is significantly more effective in reducing pain and disability in resistant lateral epicondylitis at 6 months as compared to ESWT only. This study also confirmed that there is significant improvement of ultrasound parameters in ESWT and nutraceutical supplementation group compare to ESWT only group and may be considered as a novel alternative for surgery in resistant cases.

REFERENCES

1. Jarvinen TA, Kannus P, Maffulli N, Khan KM. Achilles tendon disorders: etiology and epidemiology. *Foot Ankle Clin* 2005;10(1):255-66.
2. Xu Y, Murrell GAC. The basic science of tendinopathy. *Clin Orthop Relat Res* 2008;466(7):1528-38.
3. Terry CS, Beatty JH. Shoulder and elbow injuries. In: Terry CS, editor. *Campbell's Operative Orthopaedics*. 12th ed. Missouri: Mosby; 2008.p.2241-5.
4. Dorf ER, Chhabra AB, Golish SR, McGinty JL, Pannunzio ME. Effect of elbow position on grip strength in the evaluation of lateral epicondylitis. *J Hand Surg Am* 2007;32(6):882-6.
5. Petrone FA, Ricciardelli E. Gymnastic injuries: the Virginia experience 1982-1983. *Am J Sports Med* 1987;15(1):59-62.
6. Bharti A, Avasthi S, Solanki K, Kumar S, Swaroop A, Sengar GK. Clinical assessment of functional outcome in lateral epicondylitis managed by local infiltration of autologous blood. *Internet J Med Update* 2010;5(1):20-4.
7. Taylor SA, Hannafin JA. Evaluation and management of elbow tendinopathy. *Sports Health* 2012;4(5):384-93.
8. Kraushaar BS, Nirschl RP. Tendinosis of the elbow (tennis elbow). Clinical features and findings of histological, immunohistochemical and electron microscopy studies. *J Bone Joint Surg Am* 1999;81(2):259-78.

9. Singh A, Gangwar DS, Singh S. Injection of bone marrow concentrates for treatment of refractory tennis elbow. *Saudi J Sports Med* 2013;13(2):98-101.
10. Lake JE, Ishikawa SN. Conservative treatment of Achilles tendinopathy: emerging techniques. *Foot Ankle Clin* 2009;14(4):663-74.
11. Smidt N, Windt DAV, Assendelft WJ, Devillé WL, Bouter LM. Corticosteroid injections, physiotherapy or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. *Lancet* 2002;359(9307):657-62.
12. Alfredson H. Chronic midportion Achilles tendinopathy: an update on research and treatment. *Clin Sports Med* 2003;22(4):727-41.
13. Magnusson RA, Dunn WR, Thomson AB. Non-operative treatment of midportion Achilles tendinopathy: a systematic review. *Clin J Sport Med* 2009;19(1):54-64.
14. Vitali M, Peretti G, Mangiavini L, et al. The treatment with extracorporeal shock wave therapy in some of most frequently musculoskeletal pathologies. *J Bone Surg Brit.* 2006;8-B:423
15. Aiyegbusi AI, Duru FI, Awelimbore D, et al. The role of aqueous extract of pineapple fruit parts on the healing of acute crush tendon injury. *Nig Q J Hosp Med.* 2010;20:223-227.
16. Bokhari AR, Murrell GA. The role of nitric oxide in tendon healing. *J Shoulder Elbow Surg.* 2012;21:238-244.
17. Shakibaei M, Buhrmann C, Mobasheri A. Anti-inflammatory and anti-catabolic effects of TENDOACTIVE® on human tenocytes in vitro. *Histol Histopathol.* 2011;26:1173-1185.
18. Notarnicola A, Pesce V, Vicenti G, et al. SWAAT study: extracorporeal shock wave therapy and arginine supplementation and other nutraceuticals for insertional achilles tendinopathy. *Adv Ther.* 2012;29:799-814.
19. Chen X, Jones IA, Park C, et al. The efficacy of platelet-rich plasma on tendon and ligament healing: a systematic review and meta-analysis with bias assessment. *Am J Sports Med.* 2018;46(8):2020-2032.
20. Gani NU, Khan HA, Kamal Y, Farooq M, Jeelani H, Shah AB. Long term results in refractory tennis elbow using autologous blood. *Orthop Rev* 2014;6(4):73-6.
21. Iwasaki M, Nakahara H, Nakata K, Nakase T, Kimura T, Ono K. Regulation of proliferation and osteochondrogenic differentiation of periosteum-derived cells by transforming growth factor- and basic fibroblast growth factor. *J Bone Joint Surg Am* 1995;77(4):543-54.
22. Ahmad Z, Howard D, Brooks RA, Wardale J, Henson FM, Getgood A, et al. The role of platelet rich plasma in musculoskeletal science. *JRSM Short Rep* 2012;3(6):40-5.
23. De Mos M, Van der Windt AE, Jahr H, Van Schie HT, Weinans H, Verhaar JA, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. *Am J Sports Med* 2008;36(6):1171-8.
24. Ahmad Z, Siddiqui N, Malik SS, Abdus-Samee M, Tytherleigh-Strong G, Rushton N. Lateral epicondylitis: a review of pathology and management. *Bone Joint J* 2013;95(9):1158-64.
25. Romeo P, Lavanga V, Pagani D, et al. Extracorporeal shock wave therapy in musculoskeletal disorders a review. *Med Princ Pract.* 2013;23:7-13
26. Frassanito P, Cavalieri C, Maestri R, et al. Effectiveness of extracorporeal shock wave therapy and kinesio taping in calcific tendinopathy of the shoulder: a randomized controlled trial. *Eur J Phys Rehabil Med.* 2017;54(3):333-340.
27. Vulpiani MC, Nusca SM, Vetrano M, et al. Extracorporeal shock wave therapy vs cryoultrasound therapy in the treatment of chronic lateral epicondylitis. One year follow up study. *Muscle Ligaments and Tendons J.* 2019;05: 167-174.
28. Chou WY, Wang CJ, Wu KT, et al. Comparative outcomes of extracorporeal shockwave therapy for shoulder tendinitis or partial tears of the rotator cuff in athletes and non-athletes: Retrospective study. *Int J Surg.* 2018;51:184-190.
29. Gumina S, Passaretti D, Gurzi MD, et al. Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain in rotator cuff tear repair: a prospective randomized study. *Curr Med Res Opin.* 2012;28:1767-1774.
30. Merolla G, Dellabiancia F, Ingardia A, et al. Co-analgesic therapy for arthroscopic supraspinatus tendon repair pain using a dietary supplement containing *Boswellia serrata* and *Curcuma longa*: a prospective randomized placebo-controlled study. *Musculoskelet Surg.* 2015;99(1):S43-S52.
31. Balus R, Alvarez G, Baro F, et al. A 3-arm randomized trial for achilles tendinopathy: eccentric training, eccentric training plus a dietary supplement containing mucopolysaccharides, or passive stretching plus a dietary supplement containing mucopolysaccharides. *Curr Ther Res Clin Exp.* 2016;78:1-7.
32. Kisch T, Wuerfel W, Forstmeier V, et al. Repetitive shock wave therapy improves muscular microcirculation. *J Surg Res.* 2016;201:440-445.
33. Hatanaka K, Ito K, Shindo T, et al. Molecular mechanisms of the angiogenic effects of low-energy shock wave therapy: roles of mechanotransduction. *Am J Physiol Cell Physiol.* 2016;311.
34. Frassanito P, Cavalieri C, Maestri R, et al. Effectiveness of extracorporeal shock wave therapy and kinesio taping in calcific tendinopathy of the shoulder: a randomized controlled trial. *Eur J Phys Rehabil Med.* 2017;54(3):333-340.
35. Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. *ClinOrthopRelat Res* 2008;466(7):1539-54.
36. Johnson C. Measuring pain. Visual analog scale versus numeric pain scale: what is the difference? *J Chiropr Med* 2005;4(1):43-4.
37. Rompe JD, Overend TJ, Macdermid JC. Validation of the patient-rated tennis elbow evaluation questionnaire. *J Hand Ther* 2007;20(1):3-10.
38. Martin JI, Merino J, Atilano L. Platelet-rich plasma (PRP) in chronic epicondylitis: study protocol for a randomized controlled trial. *BMC [serial online].* 2013;14:410. Available from: <http://www.trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-410>. Accessed July 23, 2016.
39. Pattanittum P, Turner T, Green S, Buchbinder R. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. *Cochrane Database Syst Rev* 2013;5:CD003686.
40. Jindal N, Gaury Y, Banshiwal RC, Lamoria R, Bachhal V. Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. *J Orthop Surg Res* 2013;8(4):10-6.
41. Bostan B, Balta O, Murat A, Aytekin K, Eser E. Autologous blood injection works for recalcitrant lateral epicondylitis. *Balkan Med J* 2016;33(2):216-20.
42. Ricardo M, Yblin S, Giovanni O, Eilen M, Medical S. Treatment of lateral epicondylitis with autologous blood injection. *Ortho & Rheum Open Access* 2017;7(5):125-8.
43. Rawal M, Vaishya R, Ram KCB, Chand P, Verma G, Rokaya PK. Comparative study of injection autologous blood and steroid injection in the treatment of tennis elbow. *Apollo Medicine* 2017;14(1):49-56.
44. Arik HO, Kose O, Guler F, Deniz G, Egerci OF, Ucar M. Injection of autologous blood versus corticosteroid for lateral epicondylitis: a randomised controlled study. *J Orthop Surg* 2014;22(3):333-7.
45. Suresh SPS, Ali KE, Jones H, Connell DA. Medial epicondylitis: is ultrasound guided autologous blood injection an effective treatment? *Br J Sports Med* 2006;40(11):935-9.
46. Gautam VK, Verma S, Batra S, Bhatnagar N, Arora S. Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation. *J Orthop Surg* 2015;23(1):1-5.
47. Poltawski L, Watson T. Measuring clinically important change with the Patient-rated Tennis Elbow Evaluation. *Hand Ther* 2011;16(3):52-7.